现代医药卫生
現代醫藥衛生
현대의약위생
MODERN MEDICINE HEALTH
2009年
16期
2421-2422
,共2页
厄贝沙坦%依那普利%高血压
阨貝沙坦%依那普利%高血壓
액패사탄%의나보리%고혈압
Irbesartan%Enalapril%Hypertension
目的:观察厄贝沙坦治疗轻、中度原发性高血压(EH)的疗效及安全性.方法:随机将87例轻、中度原发性高血压患者分为厄贝沙坦组48例和依那普利组39例,分别接受厄贝沙坦150 mg/d或依那普利40 mg/d.治疗前后测量坐位血压,记录疗效和不良反应.结果:厄贝沙坦与依那普利均能有效降低血压,治疗总有效率分别为97.9%和97.0%,两组疗效比较,差异无显著性(P>0.05).依那普利组有6例发生干咳.结论:厄贝沙坦是治疗轻、中度原发性高血压安全有效的药物.
目的:觀察阨貝沙坦治療輕、中度原髮性高血壓(EH)的療效及安全性.方法:隨機將87例輕、中度原髮性高血壓患者分為阨貝沙坦組48例和依那普利組39例,分彆接受阨貝沙坦150 mg/d或依那普利40 mg/d.治療前後測量坐位血壓,記錄療效和不良反應.結果:阨貝沙坦與依那普利均能有效降低血壓,治療總有效率分彆為97.9%和97.0%,兩組療效比較,差異無顯著性(P>0.05).依那普利組有6例髮生榦咳.結論:阨貝沙坦是治療輕、中度原髮性高血壓安全有效的藥物.
목적:관찰액패사탄치료경、중도원발성고혈압(EH)적료효급안전성.방법:수궤장87례경、중도원발성고혈압환자분위액패사탄조48례화의나보리조39례,분별접수액패사탄150 mg/d혹의나보리40 mg/d.치료전후측량좌위혈압,기록료효화불량반응.결과:액패사탄여의나보리균능유효강저혈압,치료총유효솔분별위97.9%화97.0%,량조료효비교,차이무현저성(P>0.05).의나보리조유6례발생간해.결론:액패사탄시치료경、중도원발성고혈압안전유효적약물.
Objective:To assess the efficacy and safety of irbesartan in the treatment of essential hypertension.Methods:87 pa-tients with mild to mederate essential hypertension were divided into Irbesartan(48 cases) and enalapril group(39 cases) randomly,and re-ceived irbesartan 150 mg/d or enalapril 40 mg/d respectively.Sitting blood pressure was taken,the therapeutic effect and side effects were reconded.Results:Both irbesartsn and enalapril were effective to lower blood pressure.The therapeutic effects of two groups were 97.9% and 97% respectively (P>0.05).Six patients in enalapril group had dry cough.Condusion:Irbesartan is a safe and effective anfihyperten-sire drug for mild to moderate essential hypertension.
